(Reuters Health)—Patients with knee osteoarthritis (OA) and insomnia may be less troubled by joint pain after they get treatment to help them sleep better, a recent study suggests. Knee OA, a leading cause of pain and disability in older adults, occurs when flexible tissue at the ends of bones wears down. Although it can’t be…
Calcium Crystal Deposition in Rheumatic Diseases: Mechanisms & Evaluation of Calcium Crystal Deposits Explored
MADRID—Calcification in osteoarthritis (OA) involves a series of pathways and interactions that feed off each other in a process that bears some resemblance to the transformation of cartilage to bone that takes place in the embryonic stage of human development, a researcher said here at the 2017 Annual European Congress on Rheumatology (EULAR). “My hypothesis…
Osteoporosis Screening Is Underutilized Despite Recommendations
For years, guidelines from various organizations have recommended osteoporosis screening in women and men starting at a specific age or based on specific risk factors. Among these guidelines are those developed by the U.S. Preventive Services Task Force (USPSTF) that recommend universal osteoporosis screening for women 65 years of age and older and for targeted…
Effectiveness of Retinoic Acid, Hydroxychloroquine Examined for Hand OA
The Osteoarthritis Research Society International (OARSI) held the 2017 OARSI World Congress in Las Vegas, April 27–30. Below, we report on two of the sessions held. Retinoic Acid & Hand Osteoarthritis Retinoic acid is a vitamin A derivative and hormonal signaling molecule with a role in cartilage and skeletal development. Retinoic acid has complex function,…
Novel Bone Drug Promising in Postmenopausal Osteoporosis
NEW YORK (Reuters Health)—The investigational drug romosozumab led to gains in hip bone mineral density (BMD) that were not seen with teriparatide in older women with osteoporosis transitioning from bisphosphonate therapy in the STRUCTURE study. Amgen’s romosozumab is a monoclonal antibody that inhibits sclerosin, a negative regulator of bone formation. In addition to stimulating bone…
Online Risk Calculator for Knee OA Influences Patient Risk Perception
A new tool for assessing the risk of developing knee osteoarthritis (OA) may be useful for knee OA education. A recent study found the online risk calculator, OA Risk C, was effective in helping patients better understand their personal risk of developing the disease. It may also motivate some patients to embrace exercise-related behavior changes…
Genetic Analysis Provides Insights into How Human Growth Is Linked to OA
Research has shed light on the genetic mutations that link GDF5 with arthritis and height. An ancient regulatory variant in GROW1 has been repeatedly selected in humans in northern environments, explaining the high frequency of a GDF5 haplotype that increases arthritis susceptibility…
Collaborative Guideline Addresses the Perioperative Use of Antirheumatic Drug Therapy
A new guideline developed by the ACR and the American Association of Hip and Knee Surgeons addresses the perioperative use of antirheumatic drug therapy. Specifically, it provides recommendations on the use of traditional disease-modifying antirheumatic drugs, biologic agents, tofacitinib and glucocorticoids in adults with RA; SpA, including ankylosing spondylitis and psoriatic arthritis; JIA; or SLE undergoing elective THA or TKA. The guideline provides recommendations regarding when to continue, when to withhold and when to restart these medications, and the optimal perioperative dosing of glucocorticoids…
Soccer, Wrestling among Sports Tied to Risk of Knee Arthritis
(Reuters Health)—Participation in some sports, including soccer, wrestling and elite-level long-distance running, may increase the risk of knee osteoarthritis, researchers say. “While the typical athlete is not at a greater risk of knee osteoarthritis, it was interesting to see that certain athletes may be more likely to have knee osteoarthritis later in life, specifically, elite…
Rheumatology Drug Updates: Uncertain Future for Romosozumab, Plus FDA Approves Tocilizumab for GCA
Romosozumab’s Future Is Uncertain Romosozumab, which has the possible U.S. brand name Evenity, is awaiting approval from the FDA.1 The treatment is an investigational, injectable biologic for treating osteoporosis. It increases bone formation and bone density, reducing a patient’s risk of fractures. The manufacturer no longer expects the FDA to approve the drug this year…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 46
- Next Page »